BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2566913)

  • 1. A current analysis of behavioral problems in patients with idiopathic Parkinson's disease.
    Mayeux R
    Mov Disord; 1989; 4 Suppl 1():S48-56. PubMed ID: 2566913
    [No Abstract]   [Full Text] [Related]  

  • 2. Depression antedating the onset of Parkinson's disease.
    Fukunishi I; Hosokawa K; Ozaki S
    Jpn J Psychiatry Neurol; 1991 Mar; 45(1):7-11. PubMed ID: 1753493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression in Parkinson's disease: a biochemical model.
    Sano M; Stern Y; Cote L; Williams JB; Mayeux R
    J Neuropsychiatry Clin Neurosci; 1990; 2(1):88-92. PubMed ID: 2136066
    [No Abstract]   [Full Text] [Related]  

  • 4. The nigrostriatal system in Parkinson's disease.
    Graybiel AM; Hirsch EC; Agid Y
    Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic and neurochemical correlates of major depression and psychosis in primary dementia.
    Zubenko GS
    Int Psychogeriatr; 1996; 8 Suppl 3():219-23; discussion 269-72. PubMed ID: 9154567
    [No Abstract]   [Full Text] [Related]  

  • 6. [Senile Parkinsonism: its motor and psychological defects].
    Birkmayer W
    Aktuelle Gerontol; 1982 Sep; 12(5):166-7. PubMed ID: 6128932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotic and depressive symptoms in Parkinson's disease. A study of the growth hormone response to apomorphine.
    Mellers JD; Quinn NP; Ron MA
    Br J Psychiatry; 1995 Oct; 167(4):522-6. PubMed ID: 8829723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological aspects of depression in Parkinson's disease.
    Birkmayer W; Riederer P
    Psychopathology; 1986; 19 Suppl 2():58-61. PubMed ID: 2883700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aetiology and natural history of Parkinson's disease.
    Pearce JM
    Br Med J; 1978 Dec; 2(6153):1664-6. PubMed ID: 32952
    [No Abstract]   [Full Text] [Related]  

  • 11. [Basal ganglia lesions and neurotransmitters].
    Yoshida M
    Nihon Rinsho; 1978; 36(1):58-64. PubMed ID: 24766
    [No Abstract]   [Full Text] [Related]  

  • 12. Involvement of transmitter systems in neuropsychiatric diseases.
    Hartmann J; Künig G; Riederer P
    Acta Neurol Scand Suppl; 1993; 146():18-21. PubMed ID: 8101412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep EEG in depressed and nondepressed patients with Parkinson's disease.
    Kostic VS; Susic V; Przedborski S; Sternic N
    J Neuropsychiatry Clin Neurosci; 1991; 3(2):176-9. PubMed ID: 1821232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 15. Distinctive aspects of cognitive dysfunction in Parkinson's disease.
    Growdon JH; Corkin S; Rosen TJ
    Adv Neurol; 1990; 53():365-76. PubMed ID: 1978518
    [No Abstract]   [Full Text] [Related]  

  • 16. The psychiatric complications of Parkinson's disease.
    Whitlock FA
    Aust N Z J Psychiatry; 1986 Jun; 20(2):114-21. PubMed ID: 3464262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of transcranial sonography signal changes in the human substantia nigra.
    Double KL; Todd G; Duma SR
    Int Rev Neurobiol; 2010; 90():107-20. PubMed ID: 20692497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuronal communication breakdown in neurotransmitter systems in Alzheimer's and Parkinson's dementias.
    Chan-Palay V
    J Neurocytol; 1990 Oct; 19(5):802-6. PubMed ID: 1706418
    [No Abstract]   [Full Text] [Related]  

  • 19. Is iron involved in pathogenesis of Parkinson's disease--Mössbauer spectroscopy study of substantia nigra in control and disease brains.
    Friedman A; Bauminger ER; Gałazka-Friedman J; Barcikowska M; Hechel D; Nowik I; Marczewska M
    Neurol Neurochir Pol; 1996; 30 Suppl 2():95-103. PubMed ID: 9100247
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia.
    Rinne JO; Rummukainen J; Paljärvi L; Säkö E; Mölsä P; Rinne UK
    Prog Clin Biol Res; 1989; 317():325-32. PubMed ID: 2602422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.